Pretargeting immunotherapy

a novel treatment approach for systemic amyloidosis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The amyloidoses are a complex group of disorders characterized by the deposition of proteinaceous amyloid fibrils in vital organs. The deposits are nonimmunogenic and may be composed of one of more than 35 proteins. We have developed a two-stage immunotherapeutic approach using peptides that recognize most, if not all, amyloid deposits to facilitate amyloid clearance. In the first embodiment, we have developed a bifunctional peptope to enhance and expand the utility of currently available antibodies. In the second, we have generated peptide-reactive antibodies that can be targeted to the amyloid deposits by peptides thereby providing alternative reagents for immunotherapy of amyloidosis. These technologies provide tools for treating the many forms of amyloid disease, restoring organ function and enhancing patient survival.

Original languageEnglish (US)
Pages (from-to)215-223
Number of pages9
JournalPharmaceutical patent analyst
Volume6
Issue number5
DOIs
StatePublished - Sep 1 2017
Externally publishedYes

Fingerprint

Amyloidosis
Amyloid
Immunotherapy
Amyloid Plaques
Peptides
Antibodies
Therapeutics
Technology
Survival
Proteins

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Pretargeting immunotherapy : a novel treatment approach for systemic amyloidosis. / Wall, Jonathan; Foster, James S.; Martin, Emily; Kennel, Stephen.

In: Pharmaceutical patent analyst, Vol. 6, No. 5, 01.09.2017, p. 215-223.

Research output: Contribution to journalArticle

@article{8d6162243ed0436688d549ac9b45fb1a,
title = "Pretargeting immunotherapy: a novel treatment approach for systemic amyloidosis",
abstract = "The amyloidoses are a complex group of disorders characterized by the deposition of proteinaceous amyloid fibrils in vital organs. The deposits are nonimmunogenic and may be composed of one of more than 35 proteins. We have developed a two-stage immunotherapeutic approach using peptides that recognize most, if not all, amyloid deposits to facilitate amyloid clearance. In the first embodiment, we have developed a bifunctional peptope to enhance and expand the utility of currently available antibodies. In the second, we have generated peptide-reactive antibodies that can be targeted to the amyloid deposits by peptides thereby providing alternative reagents for immunotherapy of amyloidosis. These technologies provide tools for treating the many forms of amyloid disease, restoring organ function and enhancing patient survival.",
author = "Jonathan Wall and Foster, {James S.} and Emily Martin and Stephen Kennel",
year = "2017",
month = "9",
day = "1",
doi = "10.4155/ppa-2017-0022",
language = "English (US)",
volume = "6",
pages = "215--223",
journal = "Pharmaceutical patent analyst",
issn = "2046-8954",
publisher = "Future Science",
number = "5",

}

TY - JOUR

T1 - Pretargeting immunotherapy

T2 - a novel treatment approach for systemic amyloidosis

AU - Wall, Jonathan

AU - Foster, James S.

AU - Martin, Emily

AU - Kennel, Stephen

PY - 2017/9/1

Y1 - 2017/9/1

N2 - The amyloidoses are a complex group of disorders characterized by the deposition of proteinaceous amyloid fibrils in vital organs. The deposits are nonimmunogenic and may be composed of one of more than 35 proteins. We have developed a two-stage immunotherapeutic approach using peptides that recognize most, if not all, amyloid deposits to facilitate amyloid clearance. In the first embodiment, we have developed a bifunctional peptope to enhance and expand the utility of currently available antibodies. In the second, we have generated peptide-reactive antibodies that can be targeted to the amyloid deposits by peptides thereby providing alternative reagents for immunotherapy of amyloidosis. These technologies provide tools for treating the many forms of amyloid disease, restoring organ function and enhancing patient survival.

AB - The amyloidoses are a complex group of disorders characterized by the deposition of proteinaceous amyloid fibrils in vital organs. The deposits are nonimmunogenic and may be composed of one of more than 35 proteins. We have developed a two-stage immunotherapeutic approach using peptides that recognize most, if not all, amyloid deposits to facilitate amyloid clearance. In the first embodiment, we have developed a bifunctional peptope to enhance and expand the utility of currently available antibodies. In the second, we have generated peptide-reactive antibodies that can be targeted to the amyloid deposits by peptides thereby providing alternative reagents for immunotherapy of amyloidosis. These technologies provide tools for treating the many forms of amyloid disease, restoring organ function and enhancing patient survival.

UR - http://www.scopus.com/inward/record.url?scp=85050580140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050580140&partnerID=8YFLogxK

U2 - 10.4155/ppa-2017-0022

DO - 10.4155/ppa-2017-0022

M3 - Article

VL - 6

SP - 215

EP - 223

JO - Pharmaceutical patent analyst

JF - Pharmaceutical patent analyst

SN - 2046-8954

IS - 5

ER -